Arcellx, Inc.
ACLXDelisted Apr 28, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001786205
Arcellx, Inc. was delisted on Apr 28, 2026; its insiders filed their last Form 4 on Apr 28, 2026; 240 institutions reported holding it in 13F filings for Q1 2026, worth $6.52B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 240
- Q1 2026, +26 vs. previous quarter
- 13F value
- $6.52B
- Reported value at the end of Q1 2026
- Superinvestors holding
- 1
- At the end of Q1 2026
Superinvestors holding ACLX, Q1 2026
1 superinvestor reports holding Arcellx, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
Open-market purchases and sales by Arcellx, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 (view filing) | Feb 27 | Same day | Elghandour RamiSEE REMARKS | SSale | −89.9K | $113.92 | −$10.2M | −24.6%276.1K after | |
| Feb 25, 2026 (view filing) | Feb 25 | Same day | Gilson MichelleCHIEF FINANCIAL OFFICER | SSale | −11.2K | $113.82 | −$1.28M | −24.8%33.9K after | |
| Feb 19, 2026 (view filing) | Feb 19 | Same day | Gilson MichelleCHIEF FINANCIAL OFFICER | SSale | −8.38K | $68.29 | −$572.6K | −15.7%45.2K after | 3 lots |
| Feb 18, 2026 (view filing) | Feb 17 | 1 day | Gilson MichelleCHIEF FINANCIAL OFFICER | SSale | −11.3K | $69.50 | −$784.8K | −17.4%53.5K after | 2 lots |
| Jan 20, 2026 (view filing) | Jan 20 | Same day | Lubner David CharlesDirector | SSale | −6.00K | $75.00 | −$450.0K | −21.7%21.7K after | 10b5-1 |
| Jan 14, 2026 (view filing) | Jan 14 | Same day | Heery ChristopherCHIEF MEDICAL OFFICER | SSale | −5.88K | $68.51 | −$403.0K | −19.9%23.7K after | |
| Jan 13, 2026 (view filing) | Jan 13 | Same day | Heery ChristopherCHIEF MEDICAL OFFICER | SSale | −7.44K | $65.51 | −$487.2K | −20.1%29.6K after | |
| Jan 12, 2026 (view filing) | Jan 12 | Same day | Heery ChristopherCHIEF MEDICAL OFFICER | SSale | −6.13K | $64.15 | −$393.3K | −14.2%37.1K after | |
| Nov 17, 2025 (view filing) | Nov 17 | Same day | Heery ChristopherCHIEF MEDICAL OFFICER | SSale | −340 | $90.00 | −$30.6K | −54.5%284 after | 10b5-1 |
| Oct 15, 2025 (view filing) | Oct 15 | Same day | Gilson MichelleCHIEF FINANCIAL OFFICER | SSale | −5.36K | $91.04 | −$488.3K | −38.8%8.47K after | 10b5-1 |
Top 10 13F holders, Q1 2026
The largest institutional positions in Arcellx, Inc. at the end of Q1 2026; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 6,720,803 | $771.7M | 36.44% | 00.0% | Unchanged |
| Paradigm Biocapital Advisors LP | 5,774,016 | $663.0M | 13.55% | +50,000+0.9% | Added |
| BlackRock, Inc. | 3,945,238 | $453.0M | 0.01% | +396,451+11.2% | Added |
| NEA Management Company, LLC | 3,045,262 | $349.7M | 19.88% | 00.0% | Unchanged |
| Pentwater Capital Management LP | 2,870,000 | $329.5M | 2.34% | +2,870,000 | New |
| Vanguard Capital Management LLC | 2,425,218 | $278.5M | 0.01% | +2,425,218 | New |
| Vanguard Portfolio Management LLC | 2,424,818 | $278.4M | 0.01% | +2,424,818 | New |
| Sr One Capital Management, LP | 2,346,630 | $269.4M | 29.43% | 00.0% | Unchanged |
| FIL Ltd | 2,339,192 | $268.6M | 0.21% | +2,339,192 | New |
| HBK Investments L P | 2,278,517 | $261.6M | 3.29% | +2,278,517 | New |